L-Arginine for Dental Caries

Does arginine prevent cavities? Not proven. Almost all of the research tests arginine brushed onto the teeth, usually 1.5% arginine with a calcium compound and 1,450 ppm fluoride, and fluoride toothpaste remains the proven base. A 2015 review included 10 studies (15,546 participants) and pooled 7 of them, finding a synergistic effect of arginine with fluoride on early coronal and root caries compared with placebo or fluoride alone, but it downgraded the evidence for risk of bias and potential publication bias. A 2016 Swedish systematic review concluded there was insufficient evidence for a caries-preventive effect of putting arginine in toothpaste, citing conflicts of interest.

We found no trial of swallowed arginine capsules or powder for tooth decay, so the doses on the L-arginine page do not apply here. Treat arginine as an unproven extra on top of fluoride toothpaste and regular dental care, not as a way to prevent or treat dental caries.

Some bacteria in dental plaque break arginine down through the arginine deiminase system (ADS), releasing ammonia that raises the pH of the plaque and offsets the acid that sugars produce. That alkali production is thought to lower the risk of cavities. In a study of 100 children, plaque from healthy tooth surfaces had higher ADS activity (378.6) than plaque from dentine lesions (208.4; p < .001) or enamel lesions (194.8; p = .005), whatever the child's overall caries status.

In a small trial of 19 caries-free and 19 caries-active people, four weeks of brushing with a fluoride-free 1.5% arginine toothpaste raised plaque ADS activity in the caries-active group (P = 0.026) and moved their plaque bacteria toward the profile of caries-free people.

Higher ADS activity in healthy plaque shows an association, not that adding arginine prevents cavities. A 2018 meta-analysis found plaque and saliva ADS activity promising as caries risk indicators in adults but inconclusive in children, and the 100-child study found no difference in salivary ADS activity by caries status.

The 4-week study measured bacteria and enzyme activity, not cavities. Whether those changes translate into fewer cavities is what the toothpaste trials below were designed to test.

In the two-year toothpaste trials, children brushed twice a day with the assigned paste. The older trials used 1.5% arginine with an insoluble calcium compound and 1,450 ppm fluoride; the newest China trial used fluoride-free pastes with 8.0% or 1.5% arginine in a calcium carbonate base. The only non-toothpaste product was a daily lozenge with 2% arginine and two probiotic strains, taken for 10 to 12 months.

No trial gave arginine as a swallowed supplement for cavities, so there is no dose to quote. Shop products can differ from the trial pastes in arginine content and fluoride content, so check the label.

In Bangkok, 6,000 children aged 6 to 12 were randomized to one of two 1.5% arginine toothpastes with calcium and 1,450 ppm fluoride, or to a fluoride-only toothpaste. After 1 year there were no significant differences; after 2 years the arginine groups had 21.0% and 17.7% lower DMFT increments and 16.5% lower DMFS increments (p < 0.02). A trial in over 5,500 children in Sichuan, China found the same pattern, with 20.5% lower DMFT and 19.6% lower DMFS increments at 2 years and no difference at 1 year.

These are relative reductions in the growth of decay, and the abstracts do not give absolute counts. The Swedish review said no conclusions could be drawn from the child trials because of conflicts of interest.

A 2026 trial in 6,000 Chinese children aged 10 to 14 with at least 2 active lesions compared fluoride-free 8.0% and 1.5% arginine toothpastes with a 1,450 ppm fluoride paste for 2 years. The 8.0% paste cut DMFS increments by 26.0% (-0.16 surfaces; 95% CI -0.22 to -0.10) and DMFT by 25.3%. The 1.5% paste did not differ from fluoride (DMFS -0.01; 95% CI -0.07 to 0.05; P = .819).

The manufacturer funded the trial and took part in its design, data analysis and interpretation. It did not test arginine added to fluoride, and we found no independent repeat. There were no serious adverse events.

In 253 Brazilian adults with active root caries, 70.5% of lesions improved with a 1.5% arginine fluoride paste versus 58.1% with fluoride alone after 6 months (p = 0.038). In 331 Thai children with early enamel lesions, lesion volume was not significantly different at 3 months (p = 0.055) but fell more with arginine at 6 months (15.85 vs 20.35 mm2%; p < 0.001). Both measure lesion hardness or size, not new cavities.

The lozenge trial gave 343 children aged 5 to 9 a daily lozenge with 2% arginine and two probiotic strains or a placebo lozenge. The first report found a lower caries increase with the lozenge (p = 0.007), but a second report of the same trial (288 children, all using fluoride toothpaste) found non-significant reductions of 13.6% in caries progression (p = 0.20) and 15.3% in active lesions (p = 0.15). A corrigendum was later published for the first report, and the probiotics make it impossible to credit arginine.

The Swedish review also noted that, in several trials, the control group used non-fluoride toothpaste, which it called questionable research ethics, and that arginine toothpaste costs about 40% more than basic fluoride toothpaste. A 2015 British Dental Journal analysis described ethical and design flaws in the China and Thailand school trials. A review of the meta-analyses found methodological shortcomings, with larger effects tied to unclear randomization, and a 2020 scoping review of 39 articles said the superior results carry a high risk of bias.

The reviews split: one pools a small advantage over fluoride alone, while the Swedish review says no conclusion can be drawn. That is why this page does not rate arginine higher.

A 2015 review of 10 studies identified no specific side effects related to arginine. In the 2026 trial of 6,000 children aged 10 to 14 there were no serious adverse events; 37 children reported non-serious effects, 75.7% of them unrelated to the toothpaste, and the related or possibly related ones were toothache (4), dry mouth (2), unpalatability (2) and acne (1). That trial excluded children with an arginine allergy and pregnant or lactating participants, so it says nothing about those groups. The lozenge trial in children aged 5 to 9 found no product-related side effects, and the abstracts of the older toothpaste trials do not report adverse events.

Swallowed arginine is a different matter. In the VINTAGE MI trial, 153 people after a first heart attack were given L-arginine (goal 3 g three times a day) or placebo for 6 months; 6 people (8.6%) in the arginine group died versus none on placebo (P = .01), and enrolment was closed for safety. Mayo Clinic also lists interactions with several common medicines (see the table below), and the L-arginine page covers the supplement's other cautions.

The toothpaste trials did not test drug interactions, and the abstracts report none. The practical risk there is substitution: replacing fluoride toothpaste with an unproven alternative. The medicine interactions in the table apply to swallowed arginine, as listed by Mayo Clinic, not to toothpaste.